These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8067145)

  • 1. [The determination of the optimal inoculation dose of an oral cholera bivalent chemical vaccine in a controlled trial of the vaccination of children and adolescents].
    Sumarokov AA; Dzhaparidze MN; Eliseev IuIu; Nikitina GP; Poliakov KA; Kazakova ES; Meleshchenko MV; Tsareva NM; Reznikov IuB; Adamova GV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (5):55-60. PubMed ID: 8067145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The determination of the optimal inoculation dose of an oral cholera chemical bivalent vaccine in a controlled experiment].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Reznikov IuB; Rystsova EA; Nikitina GP; Matusevich LIa; Popov AA; Plotnikova MN; Shustov VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Dec; (12):55-62. PubMed ID: 2099071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The characteristics of the reactogenicity and immunological activity of a new cholera bivalent chemical vaccine based on the results of controlled trials].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Rystsova EA; Reznikov IuB; Matusevich LIa; Nikitina GP; Eliseev IuIu; Adamova GV; Plotnikova MN
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):55-8. PubMed ID: 1719716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An oral chemical vaccine from the hypertoxigenic strains of the causative agent of cholera KM-76 Inaba and KM-68 Ogawa].
    Dzhaparidze MN; Naumov AV; Nikitina GP; Meleshchenko MV; Dobrova GV; Zavorotnykh VI; Gracheva VP; Zakharova TL
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Apr; (4):31-3. PubMed ID: 1882603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical and immunochemical characteristics of a new oral, chemical cholera bivalent vaccine and results of a trial of the preparation on volunteers].
    Dzhaparidze MN; Nikitina GP; Ivanov NR; Rystsova EA; Udalova IB
    Zh Mikrobiol Epidemiol Immunobiol; 1982; (11):29-33. PubMed ID: 6760628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
    Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
    Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
    Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
    Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An experimental study of the safety of a chemical monovalent tableted cholera vaccine in enteral administration].
    Nazarova LS; Isupov IV; Dzhaparidze MN; Pavlova LP; Gor'kova AV; Dmitrieva VP; Chelova LA
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jan; (1):49-51. PubMed ID: 1713379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India.
    Kanungo S; Sen B; Ramamurthy T; Sur D; Manna B; Pazhani GP; Chowdhury G; Jhunjhunwala P; Nandy RK; Koley H; Bhattacharya MK; Gupta S; Goel G; Dey B; M T; Nair GB; Ghosh A; Mahalanabis D
    PLoS One; 2014; 9(7):e99381. PubMed ID: 24983989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [O-antigen of Vibrio cholerae, serovar Ogawa, Recommended for the production of oral cholera bivalent vaccine].
    Dzhaparidze MN; Karaeva LT; Sumarokov AA; Marchuk LM; Nikitina GP
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):75-81. PubMed ID: 7324656
    [No Abstract]   [Full Text] [Related]  

  • 20. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.